138813-24-8

Basic information

• Product Name: 4H,9H-Dipyrazolo[1,5-a:1,5-d]pyrazine-4,9-dione(9CI)
• Synonyms: 4H,9H-Dipyrazolo[1,5-a:1,5-d]pyrazine-4,9-dione(9CI);4H,9H-DIPYRAZOLO[1,5-A:1'',5''-D]PYRAZINE-4,9-DIONE
• CAS NO: 138813-24-8
• Molecular Formula: C₈H₄N₄O₂
• Molecular Weight: 0
• Product Categories: PIPERIDINE
• Mol File: 138813-24-8.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 4H,9H-Dipyrazolo[1,5-a:1,5-d]pyrazine-4,9-dione(9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 4H,9H-Dipyrazolo[1,5-a:1,5-d]pyrazine-4,9-dione(9CI)(138813-24-8)
• EPA Substance Registry System: 4H,9H-Dipyrazolo[1,5-a:1,5-d]pyrazine-4,9-dione(9CI)(138813-24-8)

Safety Data

• Hazardous Substances Data: 138813-24-8(Hazardous Substances Data)

Upstream product

• 1621-91-6 1H-pyrazole-3-carboxylic acid 
• 610-14-0 2-nitrobenzyl chloride 
• 7719-09-7 thionyl chloride 
• 855643-75-3 pyrazole carboxylic acid 

Downstream Products

• 138785-61-2 (-)-3(5)-Pyrazolcarboxy<2-(methoxymethyl)pyrrolidid> 
• 138785-59-8 (-)-N-Methyl-N-(1-phenylethyl)-3⁽⁵⁾-pyrazolcarboxamid 
• 138785-60-1 (+)-N-(1-Cyclohexylethyl)-N-methyl-3⁽⁵⁾-pyrazolcarboxamid 
• 305346-17-2 morpholino(1H-pyrazol-3-yl)methanone 
• 763107-94-4 1H-pyrazole-3-carboxylic acid (2-chlorophenyl)methylamide 
• 305346-22-9 N-(3,4-dichlorophenyl)-1H-pyrazole-3-carboxamide 
• 763107-52-4 2-[(1H-pyrazole-3-carbonyl)amino]thiophene-3-carboxylic acid methyl ester 
• 763108-03-8 1H-pyrazole-3-carboxylic acid methylphenylamide 
• 1621-91-6 1H-pyrazole-3-carboxylic acid 

Relevant articles and documents

Hydrotris[3-(carboxypyrrolidido)pyrazol-l-yl]borate, the first proven N3O3-hexadentate homoscorpionate ligand

The new homoscorpionate ligand, hydrotris[3-(carboxypyrrolidido)pyrazol-l-yl]borate, [Tpcpd]-, was synthesized, and it formed with lanthanide(m) ions La, Nd and Sm, structurally characterized [M(Tpcpd)JPF6 complexes, where the lanthanide ion was in a ten-coordinate enviroment consisting of one N3O3 hexadentate Tpcpd ligand, and one N2O2 tetradentate Tpcpd ligand. The Royal Society of Chemistry 2000.

Imidazo[1,2-a]pyrazine, Imidazo[1,5-a]quinoxaline and?Pyrazolo[1,5-a]quinoxaline derivatives as IKK1 and IKK2 inhibitors

The transcription nuclear factor NF-κB plays a pivotal role in chronic and acute inflammatory diseases. Among the several and diverse strategies for inhibiting NF-κB, one of the most effective approach considered by the pharmaceutical industry seems to be

NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF CYSTIC FIBROSIS

The present invention discloses compounds according to Formula I: wherein R1 is as defined herein. The present invention relates to compounds and their use in the treatment of cystic fibrosis, methods for their production, pharmaceutical compositions comprising the same, and methods of treatment cystic fibrosis by administering a compound of the invention.

THIENO[2,3-C]PYRANS AS CFTR MODULATORS

The present invention discloses compounds according to Formula I: Wherein R is as defined herein. The present invention relates to compounds and their use in the treatment of cystic fibrosis, methods for their production, pharmaceutical compositions comprising the same, and methods of treatment cystic fibrosis by administering a compound of the invention.

N-Substituted pyrazole-3-carboxamides as inhibitors of human 15-lipoxygenase

High-throughput screening was used to find selective inhibitors of human 15-lipoxygenase-1 (15-LOX-1). One hit, a 1-benzoyl substituted pyrazole-3-carboxanilide (1a), was used as a starting point in a program to develop potent and selective 15-LOX-1 inhibitors.

PYRAZOLES USEFUL IN THE TREATMENT OF INFLAMMATION

There is provided compounds of formula (I), wherein X1 to X5 have meanings given in the description, and pharmaceutically- acceptable salts thereof, which compounds are useful in the treatment of diseases in which inhibition of the a

PYRAZOLES USEFUL IN THE TREATMENT OF INFLAMMATION

There is provided compounds of formula (I), wherein R1, R2, X1, X2 and n have meanings given in the description, and pharmaceutically-acceptable salts thereof, which compounds are useful in the treatment of diseases in which inhibition of the activity of a lipoxygenase (e.g. 15-lipoxygenase) is desired and/or required, and particularly in the treatment of inflammation.

PYRAZOLE COMPOUNDS USEFUL IN THE TREATMENT OF INFLAMMATION

There is provided compounds of formula (I), wherein R1, R2, Ra and Rb have meanings given in the description, and pharmaceutically-acceptable salts thereof, which compounds are useful in the treatment of diseases in which inhibition of the activity of a lipoxygenase (e.g. 15-lipoxygenase) is desired and/or required, and particularly in the treatment of inflammation.

PYRAZOLE COMPOUNDS USEFUL IN THE TREATMENT OF INFLAMMATION

There is provided a compound of formula (I), wherein R1, R2, R3, X and Y have meanings given in the description, and pharmaceutically-acceptable salts thereof, which compounds are useful in the treatment of diseases in which inhibition of the activity of a lipoxygenase (e.g. 15-lipoxygenase) is desired and/or required, and particularly in the treatment of inflammation.

Asymmetric Catalysis, 77. - New Optically Active Pyrazole Derivatives for Enantioselective Catalysis

Starting from the amines 3-6 and the dipyrazolopyrazinedione 2, the optically active (pyrazolylmethyl)amines 11-14 have been synthesized.Furthermore, the preparation of the (+)-camphor-derived optically active pyrazole 17 is described.Pyrazoles 11-13 and 17 are introduced as chiral building blocks into the 2-(1-pyrazolyl)pyridines 30-33.The optically active compounds 23-25 are formed from 2-pyridine and 2,6-bispyridine, respectively, and (+)-3-(bromomethyl)pinane.The pyrazole derivatives 27-29 contain (+)-(1-phenylethyl)hydrazine as the optically active component.Key Words: Pyrazoles, optically active / Pyridines, 2--, 2,6-bis-, 2-(1-pyrazolyl)-